Redeye initiates coverage of Acarix. The company's significant potential hinges on its CADScor system's invention of coronary artery disease (CAD) testing, plus an attractive razor/razorblade model under which high-margin (90%) disposable patches will generate the bulk of sales. While nearer-term upside is limited by the lack of reimbursement, the scope for the CADScor system to become a new standard supports the longer-term case.
Read more and download the research update: http://bit.ly/35HGhMj
Start following companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye – Research Powered Investment Banking. https://www.redeye.se/about/
